Antibiotic, Antiviral/Anti–COVID-19, and Antifungal Drugs

Core Concepts

Antibiotics that attack the cell wall

The bacterial peptidoglycan cell wall has no human equivalent, making it an ideal target. Beta-lactams — penicillins, cephalosporins, carbapenems, monobactams — block peptidoglycan cross-linking, so growing bacteria burst. Glycopeptides (such as vancomycin) bind peptidoglycan building blocks directly and stop wall assembly. Allergy — especially to penicillins — is a central nursing assessment: patients are asked about previous reactions because beta-lactam cross-reactivity is a real concern evaluated per current references.

Antibiotics that stop protein synthesis

Bacterial ribosomes differ from human ribosomes (70S versus 80S), so drugs that bind them halt protein production with relative selectivity. Macrolides (e.g., azithromycin), tetracyclines (e.g., doxycycline), and clindamycin bind the 50S or 30S subunit and stop protein synthesis; aminoglycosides (e.g., gentamicin) bind the 30S subunit and cause misreading of the genetic code. Class-level cautions matter: aminoglycosides carry kidney and hearing (ototoxicity) concerns; tetracyclines have notable interactions and age-related cautions — verify specifics against current references.

Antibiotics that block nucleic acid or folate synthesis

Some antibiotics stop bacteria from making DNA or its precursors. Fluoroquinolones (e.g., ciprofloxacin) inhibit bacterial topoisomerase enzymes that unwind DNA during replication. Sulfonamides and trimethoprim block sequential steps of folate synthesis, which bacteria must build themselves (human cells take folate from food). Drugs that stop growth without killing are bacteriostatic; those that kill directly are bactericidal — the distinction matters because the immune system must finish the job.

Spectrum, resistance, and stewardship

Narrow-spectrum antibiotics target a limited range of bacteria (often chosen once the organism is known); broad-spectrum agents cover many organisms and are used when the pathogen is unknown. Broader is not better: broad drugs disturb more normal flora, inviting superinfections such as Clostridium difficile colitis. Resistance arises through several mechanisms — bacteria may destroy the drug with enzymes (beta-lactamases), pump it out (efflux pumps), or change the drug's target. Stewardship promotes cultures before treatment, de-escalation to the narrowest effective drug, and correct duration; nurses support it by collecting cultures, questioning inappropriate orders, and teaching patients to finish courses.

Antivirals: interrupting the viral lifecycle

Because viruses hijack host cells, antivirals target viral proteins at each lifecycle step: entry inhibitors stop the virus binding or fusing with the cell; polymerase inhibitors (often nucleoside/nucleotide analogs) halt genome copying; protease inhibitors block the cutting of viral proteins; neuraminidase inhibitors (for influenza) stop new viruses being released; and integrase inhibitors (for HIV) stop the viral genome inserting into host DNA. Antiviral therapy works best started early and requires strict adherence to prevent resistance.

Anti–COVID-19 drugs: a fast-moving field

COVID-19 treatments have included antivirals that disrupt SARS-CoV-2 replication, spike-directed monoclonal antibodies (used mainly early in illness, with availability shifting as variants emerged), and immunomodulators such as corticosteroids for hospitalized patients with harmful inflammation. Because the virus mutates and guidance changes rapidly, understand the mechanism categories and always check current national and institutional guidance. Nursing care centers on supportive care, respiratory monitoring, infection prevention, and vaccination.

Antifungals: exploiting ergosterol

Fungal cells are eukaryotic, so the therapeutic window is narrow. The main target is ergosterol, the fungal-specific membrane sterol: azoles (e.g., fluconazole) inhibit the enzyme that synthesizes it, while polyenes (e.g., amphotericin B) bind it directly and damage the membrane. Echinocandins take a different approach, inhibiting fungal cell wall synthesis (a structure human cells lack). Azoles are well known for drug interactions and polyenes for infusion reactions and kidney effects — both reasons antifungal therapy needs close monitoring and medication review per orders.

Nursing considerations

• Culture before antibiotics when ordered, so therapy can be targeted.
• Allergy assessment: ask about previous reactions (especially penicillins and sulfonamides) and document clearly.
• Monitoring: Some classes require bloodwork (e.g., kidney function for aminoglycosides, drug levels where applicable) per prescriber orders.
• Adherence: teach patients to finish the full course, take doses on time, and report worsening symptoms or new rashes.
• Stewardship and scope: follow institutional stewardship programs and verify every product, dose, and route against current references, the formulary, and prescriber orders; person-first language and scope rules apply throughout.

Clinical Scenario: The Pneumonia Workup

A patient is admitted with fever, cough, and shortness of breath. The nurse collects blood and sputum cultures before the first antibiotic dose — preserving the chance to identify the organism. Because the patient is unstable and the organism unknown, the prescriber orders a broad-spectrum antibiotic to cover likely bacteria immediately; the nurse checks allergy history, reviews kidney function, and administers the first dose per orders.

Two days later the culture identifies a gram-negative organism sensitive to a much narrower drug, and the team de-escalates to it — sparing normal flora and reducing resistance pressure. The nurse teaches the patient to finish the full course and report new symptoms. Nothing here involves memorized doses: the reasoning is mechanism, the authority is the culture and the prescriber, and the safety net is monitoring, allergy review, and stewardship.

Common Confusions